Vanguard Personalized Indexing Management LLC Grows Stake in Biogen Inc. $BIIB

Vanguard Personalized Indexing Management LLC lifted its stake in Biogen Inc. (NASDAQ:BIIB) by 10.7% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 38,674 shares of the biotechnology company’s stock after purchasing an additional 3,746 shares during the quarter. Vanguard Personalized Indexing Management LLC’s holdings in Biogen were worth $5,417,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds also recently bought and sold shares of BIIB. Elevation Point Wealth Partners LLC purchased a new stake in shares of Biogen during the second quarter valued at approximately $25,000. Rothschild Investment LLC grew its stake in shares of Biogen by 64.7% during the 2nd quarter. Rothschild Investment LLC now owns 224 shares of the biotechnology company’s stock valued at $28,000 after purchasing an additional 88 shares during the period. Concord Wealth Partners grew its position in Biogen by 100.0% during the second quarter. Concord Wealth Partners now owns 228 shares of the biotechnology company’s stock valued at $29,000 after buying an additional 114 shares during the period. True Wealth Design LLC grew its position in shares of Biogen by 62.9% during the 3rd quarter. True Wealth Design LLC now owns 233 shares of the biotechnology company’s stock valued at $33,000 after acquiring an additional 90 shares during the period. Finally, NewSquare Capital LLC grew its holdings in Biogen by 134.6% during the second quarter. NewSquare Capital LLC now owns 244 shares of the biotechnology company’s stock valued at $31,000 after purchasing an additional 140 shares during the period. Institutional investors own 87.93% of the company’s stock.

Biogen Stock Down 1.4%

Biogen stock traded down $2.47 during mid-day trading on Wednesday, reaching $171.66. 90,656 shares of the company were exchanged, compared to its average volume of 1,517,423. The company has a debt-to-equity ratio of 0.35, a quick ratio of 2.04 and a current ratio of 2.72. The firm has a market cap of $25.18 billion, a P/E ratio of 15.64, a PEG ratio of 1.44 and a beta of 0.13. Biogen Inc. has a 12-month low of $110.04 and a 12-month high of $190.20. The business has a fifty day moving average of $176.08 and a 200 day moving average of $153.99.

Biogen (NASDAQ:BIIB) last announced its earnings results on Thursday, October 30th. The biotechnology company reported $4.81 EPS for the quarter, topping analysts’ consensus estimates of $3.89 by $0.92. Biogen had a net margin of 15.98% and a return on equity of 14.13%. The business had revenue of $2.53 billion during the quarter, compared to the consensus estimate of $2.34 billion. During the same period in the previous year, the company posted $4.08 earnings per share. The firm’s revenue was up 2.8% on a year-over-year basis. Biogen has set its FY 2025 guidance at 14.500-15.00 EPS. Research analysts anticipate that Biogen Inc. will post 15.83 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

BIIB has been the subject of a number of recent analyst reports. Stifel Nicolaus upgraded shares of Biogen from a “hold” rating to a “buy” rating and upped their price target for the stock from $144.00 to $202.00 in a research report on Thursday, November 6th. Jefferies Financial Group lifted their target price on Biogen from $190.00 to $210.00 and gave the stock a “buy” rating in a report on Friday, November 28th. Wall Street Zen cut shares of Biogen from a “buy” rating to a “hold” rating in a research report on Sunday, November 9th. Robert W. Baird reduced their price objective on Biogen from $255.00 to $250.00 in a research note on Friday, October 31st. Finally, HSBC reaffirmed a “reduce” rating and set a $143.00 price objective (down from $144.00) on shares of Biogen in a research note on Wednesday, December 10th. Ten research analysts have rated the stock with a Buy rating, fifteen have issued a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, Biogen presently has a consensus rating of “Hold” and an average price target of $192.04.

About Biogen

Biogen Inc is a multinational biotechnology company focused on discovering, developing and delivering therapies for neurological and neurodegenerative diseases. Headquartered in Cambridge, Massachusetts, the company has a longstanding emphasis on neuroscience, with research and commercial activities spanning multiple therapeutic areas including multiple sclerosis, spinal muscular atrophy and Alzheimer’s disease. Biogen was founded in 1978 and has grown into a global biopharmaceutical firm with operations and commercial presence across North America, Europe, Japan and other international markets.

The company’s marketed portfolio has historically included several well-known therapies for multiple sclerosis such as Avonex, Tysabri and Tecfidera, and it has pursued treatments for rare neurological conditions and genetic neuromuscular disorders.